Actively Recruiting
F-18 Tetrafluoroborate PET/CT in Differentiated Thyroid Cancer
Led by Ankara University · Updated on 2026-02-27
50
Participants Needed
2
Research Sites
47 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In patients who have undergone surgery for differentiated thyroid cancer and who demonstrate elevated serum Tg and/or ATg levels during follow-up after radioactive iodine therapy, lesion detection is performed using neck ultrasonography, thorax CT, and F-18 FDG PET/CT. Diagnostic whole-body scanning with low-dose I-131 is not routinely recommended in follow-up due to its low sensitivity and specificity. F-18 TFB is a highly specific imaging agent for differentiated thyroid cancer, entering thyroid follicular epithelial cells via the sodium-iodide symporter (NIS), which is expressed on the cell surface and functions through a mechanism similar to that of I-131. As a PET radiotracer, F-18 TFB has been shown to be superior to I-131 in previous studies. The primary aim of this study is to comparatively evaluate the role of F-18 TFB PET/CT versus the standard imaging modality F-18 Fluorodeoxyglucose (FDG) PET/CT in lesion detection in patients with differentiated thyroid cancer who demonstrate elevated serum Tg and/or ATg levels during follow-up after radioactive iodine therapy. The secondary aims are to investigate the factors predicting F-18 TFB PET/CT positivity and to assess the relationship between the semi-quantitative and quantitative parameters derived from F-18 TFB PET/CT and serum thyroglobulin (Tg) and anti-thyroglobulin (ATg) levels.
CONDITIONS
Official Title
F-18 Tetrafluoroborate PET/CT in Differentiated Thyroid Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have undergone surgery for differentiated thyroid cancer and received radioactive iodine therapy
- Being evaluated for lesion detection due to elevated serum Tg and/or ATg levels during post-treatment follow-up
- Have negative or unclear I-131 whole-body scan results
- Karnofsky Performance Status of 50 or higher (or equivalent ECOG/WHO status)
- Provide written informed consent
You will not qualify if you...
- Under 18 years of age
- Pregnant or breastfeeding
- Unable or unwilling to provide written informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Ankara University Medical School Nuclear Medicine Department
Ankara, Ankara, Turkey (Türkiye), 06590
Actively Recruiting
2
Hacettepe University Medical School Nuclear Medicine Department
Ankara, Ankara, Turkey (Türkiye), 06590
Actively Recruiting
Research Team
M
Mine Araz, Assoc.Prof.Dr.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here